Andrew Hetherington

Andrew Hetherington was named Executive Vice President, Chemistry Manufacturing and Control Development and Technical Operations (CMC/TO) at Urovant Sciences, having joined the company in January 2021. In this role, he is responsible for all aspects of CMC/TO activities to support the clinical and commercial programs for the innovative Biologics and Small Molecule portfolio at Urovant Sciences. Mr. Hetherington serves as a member of the Urovant Executive Leadership Team and the Research & Development Leadership Team.

Mr. Hetherington has more than 30 years of development, manufacturing and supply chain operations leadership experience in the biopharmaceutical industry. Prior to joining Urovant Sciences, Mr. Hetherington served as Senior Vice President of Technical Operations at Catalyst Biosciences. Earlier in his career, he also held senior CMC/TO positions at Novartis Vaccines & Diagnostics, Bayer HealthCare, and GSK.

Mr. Hetherington earned a Bachelor of Science in chemical engineering and chemistry from Monash University in Australia and an MBA in finance, operations management, and general management from the Wharton School at the University of Pennsylvania.